DoD Duchenne Muscular Dystrophy Therapeutic Idea Award
The summary for the DoD Duchenne Muscular Dystrophy Therapeutic Idea Award grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
DoD Duchenne Muscular Dystrophy Therapeutic Idea Award: The DMDRP Therapeutic Idea Award mechanism was offered in FY12 and FY14, and is being offered again in FY15. It is designed to promote new ideas that are still in the early stages of development with the potential to yield high-impact data and new avenues of investigation for novel therapeutics for DMD treatment. This award mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in DMD therapeutics. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.
Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data.
Innovation and Impact are the most important aspects of the Therapeutic Idea Award.
Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapies for DMD (e.g., drug repurposing studies). Innovative research may include high-risk approaches to DMD research. Research that is investigating the next logical step or is an incremental advance upon published data is not considered innovative.
Impact: Research that has high potential to significantly impact development of therapeutics for DMD.
Biomarker Studies
For projects addressing the FY15 DMDRP Focus Area of “discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers,” a biological marker, or biomarker, is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention.1 For the purpose of this award, biomarker qualification is defined as the evidentiary fit-for-purpose process of correlating a biomarker with the effects of an agent on biological processes and clinical endpoints.2 The DMDRP encourages the discovery and study of biomarkers that can be detected through minimally invasive procedures (e.g., blood, urine, tissue, imaging, etc.). Examples of biomarkers may include signatures of genetic or epigenetic changes, specifically expressed genes, proteins, or metabolites, and molecular, physiological, and/or imaging entities, among others.
Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data.
Innovation and Impact are the most important aspects of the Therapeutic Idea Award.
Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapies for DMD (e.g., drug repurposing studies). Innovative research may include high-risk approaches to DMD research. Research that is investigating the next logical step or is an incremental advance upon published data is not considered innovative.
Impact: Research that has high potential to significantly impact development of therapeutics for DMD.
Biomarker Studies
For projects addressing the FY15 DMDRP Focus Area of “discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers,” a biological marker, or biomarker, is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention.1 For the purpose of this award, biomarker qualification is defined as the evidentiary fit-for-purpose process of correlating a biomarker with the effects of an agent on biological processes and clinical endpoints.2 The DMDRP encourages the discovery and study of biomarkers that can be detected through minimally invasive procedures (e.g., blood, urine, tissue, imaging, etc.). Examples of biomarkers may include signatures of genetic or epigenetic changes, specifically expressed genes, proteins, or metabolites, and molecular, physiological, and/or imaging entities, among others.
Federal Grant Title: | DoD Duchenne Muscular Dystrophy Therapeutic Idea Award |
Federal Agency Name: | Dept of the Army USAMRAA |
Grant Categories: | Science and Technology |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | W81XWH-15-DMDRP-TIA |
Type of Funding: | Cooperative Agreement, Grant |
CFDA Numbers: | 12.420 |
CFDA Descriptions: | Military Medical Research and Development |
Current Application Deadline: | Oct 21, 2015 |
Original Application Deadline: | Oct 21, 2015 |
Posted Date: | Jun 4, 2015 |
Creation Date: | Jun 4, 2015 |
Archive Date: | Nov 20, 2015 |
Total Program Funding: | $480,000 |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | 1 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- Grant Announcement Contact
- CDMRP Help Desk
Phone: 301-682-5507
CDMRP Help Desk
Dept. of the Army -- USAMRAA 301-619-7144 - Similar Government Grants
- • DoD Peer Reviewed Medical, Impact Award
- • DoD Peer Reviewed Medical, Lifestyle and Behavioral Health Interventions Research Award
- • DoD Peer Reviewed Medical, Discovery Award
- • DoD Peer Reviewed Medical, Technology/Therapeutic Development Award
- • DoD Peer Reviewed Medical, Clinical Trial Award
- • FY2006 Deployed War Fighter Protection Research Program
- • Department of Defense (DOD) Fiscal Year 2003 (FY03) Breast Cancer Research Program (BCRP)C...
- • Department of Defense (DOD) Fiscal Year 2004 (FY04) Breast Cancer Research Program (BCRP) ...
- More Grants from the Dept of the Army USAMRAA
- • Spinal Cord Injury Research Program Clinical Translation Research Award
- • Spinal Cord Injury Research Program Clinical Trial Award
- • DoD Hearing Restoration Focused Research Award
- • DOD Spinal Cord Injury Research Program Translational Research Award
- • DoD Autism, Clinical Trial Award